Literature DB >> 27467227

Penile Squamous Cell Carcinoma: Penis-Preserving Treatment With Mohs Micrographic Surgery.

Mac Machan1, David Brodland, John Zitelli.   

Abstract

BACKGROUND: There have been few published case series of penile squamous cell carcinoma (SCC) removed with Mohs micrographic surgery (MMS). Of these case series, the published cure rates are between 68% and 74%.
OBJECTIVE: To report 30 years of experience removing penile SCCs with MMS. METHODS AND MATERIALS: Retrospective record review of 42 patients with 44 penile SCCs.
RESULTS: There was one recurrence of the 19 primary SCCs in situ, resulting in a cure rate of 94.7%. There were no recurrences among the 10 primary invasive SCC. Of the 6 recurrent invasive SCCs, 2 recurred, resulting in an initial cure rate of 66.7%. These 2 recurrences were re-treated with MMS with no evidence of recurrence at 5 years. There were 4 patients with SCC in situ of the glans with extension down the urethra. While all 4 patients required urethral dilation postoperatively secondary to urethral stricture, none of these tumors recurred and normal function was restored in each case.
CONCLUSION: In conclusion, MMS may be preferred for patients with penile carcinoma by providing a high cure rate and tissue conservative alternative to partial or total penectomy and does not need to be limited to low-grade, small, superficial tumors.

Entities:  

Mesh:

Year:  2016        PMID: 27467227     DOI: 10.1097/DSS.0000000000000795

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  5 in total

1.  Mohs micrographic surgery for penile carcinoma with urethral invasion: A multidisciplinary approach.

Authors:  Andres M Erlendsson; Britney N Wilson; Phyllis Bellia; William Phillips; Laura Leddy; Anthony M Rossi
Journal:  J Am Acad Dermatol       Date:  2020-04-11       Impact factor: 11.527

Review 2.  What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes.

Authors:  Vasileios I Sakalis; Riccardo Campi; Lenka Barreto; Herney Garcia Perdomo; Isabella Greco; Łukasz Zapala; Mithun Kailavasan; Tiago Antunes-Lopes; Jack David Marcus; Kenneth Manzie; John Osborne; Benjamin Ayres; Luc M F Moonen; Andrea Necchi; Juanita Crook; Pedro Oliveira; Lance C Pagliaro; Chris Protzel; Arie S Parnham; Maarten Albersen; Curtis A Pettaway; Philippe E Spiess; Scott T Tagawa; R Bryan Rumble; Oscar R Brouwer
Journal:  Eur Urol Open Sci       Date:  2022-05-02

Review 3.  Penile sparing therapy for penile cancer.

Authors:  Henry Han-I Yao; Shomik Sengupta; Justin Chee
Journal:  Transl Androl Urol       Date:  2020-12

4.  High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis.

Authors:  Nicolas Martz; Yohan Bodokh; Mathieu Gautier; Brice Thamphya; Renaud Schiappa; Daniel Lam Cham Kee; Daniel Chevallier; Arthur Hannoun; Marie-Eve Chand; Jean-Michel Hannoun-Levi
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-17

Review 5.  Penile-sparing modalities in the management of low-stage penile cancer.

Authors:  Paurush Babbar; Nitin Yerram; Alice Crane; Daniel Sun; Kyle Ericson; Andrew Sun; Abhinav Khanna; Hadley Wood; Andrew Stephenson; Kenneth Angermeier
Journal:  Urol Ann       Date:  2018 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.